Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

HOPA 2018 | Ruxolitinib and ibrutinib: the future for GvHD treatment?

Katie Gatwood • 21 Mar 2018
HOPA 2018
General Ibrutinib Ruxolitinib

At present, the standard frontline therapy of steroids for graft versus host disease (GvHD) has shown to be ineffective for many patients. Now, speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Katie Gatwood, PharmD, BCOP, of Vanderbilt University Medical Center, Nashville, TN, provides an interesting update on the use of ibrutinib or ruxolitinib for the treatment GvHD. Dr Gatwood gives an insight on current studies that are investigating the use of ruxolitinib for acute and chronic GvHD, with the hope of ruxolitinib becoming FDA approved in the future.

More from Katie Gatwood

Treating GvHD: current challenges and newly approved drugs
1:09
Treating GvHD: current challenges and newly approved drugs
Katie Gatwood • 21 Mar 2018
The importance of pharmacist intervention in the treatment of GvHD with ruxolitinib and ibrutinib
1:43
The importance of pharmacist intervention in the treatment of GvHD with ruxolitinib and ibrutinib
Katie Gatwood • 21 Mar 2018

Related Videos

The ethical challenges of AI in hematology: patient communication, trust and regulation
3:12
The ethical challenges of AI in hematology: patient communication, trust and regulation
Adrián Mosquera Orgueira • 24 Sep 2026
The future of AI in hematology: personalized medicine, opportunities and risks
2:30
The future of AI in hematology: personalized medicine, opportunities and risks
Adrián Mosquera Orgueira • 24 Sep 2026
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
5:18
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
Shyam Patel • 13 Oct 2026
The scientific and clinical implications of therapy-related CHIP in oncology
2:43
The scientific and clinical implications of therapy-related CHIP in oncology
Shyam Patel • 13 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals